Abstract:Background: In Huntington's disease clinical trials, recruitment and stratification approaches primarily rely on genetic load, cognitive and motor assessment scores. They focus less on in vivo brain imaging markers, which reflect neuropathology well before clinical diagnosis. Machine learning methods offer a degree of sophistication which could significantly improve prognosis and stratification by leveraging multimodal biomarkers from large datasets. Such models specifically tailored to HD gene expansion carriers could further enhance the efficacy of the stratification process. Objectives: To improve stratification of Huntington's disease individuals for clinical trials. Methods: We used data from 451 gene positive individuals with Huntington's disease (both premanifest and diagnosed) from previously published cohorts (PREDICT, TRACK, TrackON, and IMAGE). We applied whole-brain parcellation to longitudinal brain scans and measured the rate of lateral ventricular enlargement, over 3 years, which was used as the target variable for our prognostic random forest regression models. The models were trained on various combinations of features at baseline, including genetic load, cognitive and motor assessment score biomarkers, as well as brain imaging-derived features. Furthermore, a simplified stratification model was developed to classify individuals into two homogenous groups (low risk and high risk) based on their anticipated rate of ventricular enlargement. Results: The predictive accuracy of the prognostic models substantially improved by integrating brain imaging features alongside genetic load, cognitive and motor biomarkers: a 24 % reduction in the cross-validated mean absolute error, yielding an error of 530 mm3/year. The stratification model had a cross-validated accuracy of 81 % in differentiating between moderate and fast progressors (precision = 83 %, recall = 80 %). Conclusions: This study validated the effectiveness of machine learning in differentiating between low- and high-risk individuals based on the rate of ventricular enlargement. The models were exclusively trained using features from HD individuals, which offers a more disease-specific, simplified, and accurate approach for prognostic enrichment compared to relying on features extracted from healthy control groups, as done in previous studies. The proposed method has the potential to enhance clinical utility by: i) enabling more targeted recruitment of individuals for clinical trials, ii) improving post-hoc evaluation of individuals, and iii) ultimately leading to better outcomes for individuals through personalized treatment selection.

Optimizing Screening for Intrastriatal Interventions in Huntington's Disease Using Predictive Models

Prognostic enrichment for early-stage Huntington's disease: An explainable machine learning approach for clinical trial

Validating a Predictive Model of Acute Advanced Imaging Biomarkers in Ischemic Stroke

Volumetric MRI-Based Biomarkers in Huntington's Disease: An Evidentiary Review

Neuroimaging biomarkers in Huntington's disease: Preparing for a new era of therapeutic development

Automated Huntington's Disease Prognosis via Biomedical Signals and Shallow Machine Learning

Striatal morphology and neurocognitive dysfunction in Huntington disease: The IMAGE-HD study

Large-scale screening of clinical assessments to distinguish between states in the Integrated HD Progression Model (IHDPM)

Identifying a Whole‐brain Connectome‐based Model in Drug‐naïve Parkinson's Disease for Predicting Motor Impairment

Brain Volumetric Analysis Using Artificial Intelligence Software in Premanifest Huntington's Disease Individuals from a Colombian Caribbean Population

Huntington disease: natural history, biomarkers and prospects for therapeutics

Penalized nonlinear mixed effects model to identify biomarkers that predict disease progression

Using Wearable Sensors and Machine Learning to Assess Upper Limb Function in Huntington's Disease

The contribution of preclinical magnetic resonance imaging and spectroscopy to Huntington's disease

Differential Changes in Functional Connectivity of Striatum-Prefrontal and Striatum-Motor Circuits in Premanifest Huntington’s Disease

Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis

The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease

The effect of multidisciplinary rehabilitation on brain structure and cognition in Huntington's disease: an exploratory study

Interplay between Sex and Disease Burden in Huntington's Disease: Clinical and Neuroimaging Perspectives

Linking White Matter and Deep Gray Matter Alterations in Premanifest Huntington Disease.

Factors Influencing the Total Functional Capacity Score as a Critical Endpoint in Huntington's Disease Research